Journal of Clinical Medicine

Journal Browser

► Journal Browser

Cardiomyopathy: Current Approach and Potential Diagnostic and Therapeutic Targets

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (25 September 2021) | Viewed by 8162

Share This Special Issue

Special Issue Editor

Prof. Dr. Federico Guerra

E-Mail Website
Guest Editor

Cardiology and Arrhythmology Clinic, Department of Biomedical Sciences and Public Health, Marche Polytechnic University, University Hospital “Ospedali Riuniti Umberto I – Lancisi – Salesi”, Ancona, Italy
Interests: arrhythmias; cardiomyopathy; ECG; heart disease; heart failure; sudden cardiac death

Special Issue Information

Dear Colleagues,

Cardiomyopathies are a heterogeneous group of cardiac disorders that often leads to heart failure and arrhythmic complications. They usually exhibit dilatation and/or hypertrophy of one or both ventricles and are due to a variety of causes that are frequently genetic. There has been substantial progress in the clinical recognition and understanding of the natural history of cardiomyopathies in recent years, as their causes were clarified, and more diagnostic tools became available. Despite cardiomyopathies are now recognized with increasing frequency, there is still need for important advances in this field. Pathogenesis and physiopathology of many cardiomyopathies still need to be elucidated and new techniques of cardiac imaging must be honed. Additionally, the definition of reliable, multi-parametric diagnostic and prognostic approaches is critical for improving our patients’ well-being and survival. Such parameters should be easy to collect, reproducible and fast to implement in clinical practice. Moreover, for each cardiomyopathy, it is needed to detail long term prognosis and all the potential associations with other cardiac and non-cardiac comorbidities.

Moreover, pharmacological, interventional and device-oriented options are on the rise in heart failure patients with cardiomyopathy, each of those with potential pros and cons. Therefore, a more critical and patient-tailored approach to therapeutic management is mandatory.

Dr. Federico Guerra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

Arrhythmias
arrhythmogenic right ventricular cardiomyopathy
cardiomyopathies
diastolic dysfunction
dilated cardiomyopathy
heart failure
hypertrophic cardiomyopathy
restrictive cardiomyopathy
systolic dysfunction

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

12 pages, 1583 KiB

Open AccessArticle

Usefulness of the MAGGIC Score in Predicting the Competing Risk of Non-Sudden Death in Heart Failure Patients Receiving an Implantable Cardioverter-Defibrillator: A Sub-Analysis of the OBSERVO-ICD Registry

by Marco Canepa, Pietro Palmisano, Gabriele Dell’Era, Matteo Ziacchi, Ernesto Ammendola, Michele Accogli, Eraldo Occhetta, Mauro Biffi, Gerardo Nigro, Pietro Ameri, Giulia Stronati, Italo Porto, Antonio Dello Russo and Federico Guerra

J. Clin. Med. 2022, 11(1), 121; https://doi.org/10.3390/jcm11010121 - 27 Dec 2021

Cited by 3 | Viewed by 2022

Abstract

The role of prognostic risk scores in predicting the competing risk of non-sudden death in heart failure patients with reduced ejection fraction (HFrEF) receiving an implantable cardioverter-defibrillator (ICD) is unclear. To this goal, we evaluated the accuracy and usefulness of the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score. The present analysis included 1089 HFrEF ICD recipients enrolled in the OBSERVO-ICD registry (NCT02735811). During a median follow-up of 36 months (1st–3rd IQR 25–48 months), 193 patients (17.7%) experienced at least one appropriate ICD therapy, and 133 patients died (12.2%) without experiencing any ICD therapy. The frequency of patients receiving ICD therapies was stable around 17–19% across increasing tertiles of 3-year MAGGIC probability of death, whereas non-sudden mortality increased (6.4% to 9.8% to 20.8%, p < 0.0001). Accuracy of MAGGIC score was 0.60 (95% CI, 0.56–0.64) for the overall outcome, 0.53 (95% CI, 0.49–0.57) for ICD therapies and 0.65 (95% CI, 0.60–0.70) for non-sudden death. In patients with higher 3-year MAGGIC probability of death, the increase in the competing risk of non-sudden death during follow-up was greater than that of receiving an appropriate ICD therapy. Results were unaffected when analysis was limited to ICD shocks only. The MAGGIC risk score proved accurate and useful in predicting the competing risk of non-sudden death in HFrEF ICD recipients. Estimation of mortality risk should be taken into greater consideration at the time of ICD implantation. Full article

(This article belongs to the Special Issue Cardiomyopathy: Current Approach and Potential Diagnostic and Therapeutic Targets)

► Show Figures

Figure 1

Review

Jump to: Research

11 pages, 1262 KiB

Open AccessReview

Thyroid Hormones—An Underestimated Player in Dilated Cardiomyopathy?

by Karolina Zawadzka, Radosław Dziedzic, Andrzej Surdacki and Bernadeta Chyrchel

J. Clin. Med. 2021, 10(16), 3618; https://doi.org/10.3390/jcm10163618 - 16 Aug 2021

Cited by 4 | Viewed by 5350

Abstract

Dilated cardiomyopathy (DCM) is the most prevalent cardiomyopathy, typified by left ventricular dilation and systolic dysfunction. Many patients with DCM have altered thyroid status, especially lower levels of free triiodothyronine (T3) and elevated levels of thyroid-stimulating hormone. Moreover, growing evidence indicates that even subtle changes in thyroid status (especially low T3) are linked with a worse long-term prognosis and a higher risk of mortality. Notably, recent discoveries have shown that not only local myocardial thyroid hormones (THs) bioavailability could be diminished due to impaired expression of the activating deiodinase, but virtually all genes involved in TH biosynthesis are also expressed in the myocardium of DCM patients. Importantly, some studies have suggested beneficial effects of TH therapy in patients suffering from DCM. Our aim was to discuss new insights into the association between TH status and prognosis in DCM, abnormal expression of genes involved in the myocardial synthesis of TH in DCM, and the potential for TH use in the future treatment of DCM. Full article

(This article belongs to the Special Issue Cardiomyopathy: Current Approach and Potential Diagnostic and Therapeutic Targets)

► Show Figures